Grant of options
Oxford, UK -
04 October 2024: Oxford Biomedica plc
("OXB" or the "Company"; LSE: OXB), a quality and
innovation-led cell and gene therapy CDMO, today
announces that on 03 October 2024 nil-cost share options over
ordinary shares of 50 pence each in the Company were granted under
the OXB 2024 Long Term Incentive Plan ("LTIP").
2024 LTIP
Awards
|
Name of individual
|
Title
|
Number of shares subject to the DBP/LTIP
award prior to 2024 award
|
Number of shares subject to the 2024
LTIP award
|
Total shares over which options now
held
|
Percentage of current issued share
capital under option
|
|
Frank
Mathias
|
Chief
Executive Officer
|
323,178
|
257,113
|
580,291
|
0.55%
|
|
Lucinda
Crabtree
|
Chief
Financial Officer
|
-
|
170,113
|
170,113
|
0.16%
|
|
Sebastien
Ribault
|
Chief
Business Officer
|
66,903
|
58,406
|
125,309
|
0.12%
|
|
Thierry
Cournez
|
Chief
Operating Officer
|
66,437
|
51,570
|
118,007
|
0.11%
|
|
Lisa
James
|
Chief
People Officer
|
99,989
|
40,464
|
140,453
|
0.13%
|
|
Kyriacos
Mitrophanous
|
Chief
Innovation Officer
|
179,433
|
52,651
|
232,084
|
0.22%
|
|
Natalie
Walter
|
Group
General Counsel and Company Secretary
|
152,818
|
49,169
|
201,987
|
0.19%
|
In line with best practice, the
award granted to Frank Mathias was scaled back from 200% of salary
to 160% of salary, with the same proportionate scale back applied
to below board grantees. As a newly appointed Director, Lucinda
Crabtree's award was scaled back from 175% of salary to 157.5% of
salary.
The Remuneration Committee has
determined that EBITDA margin and revenue growth are the key
metrics aligned with the growth strategy. Therefore, for this grant
the performance conditions will be based on those metrics, weighted
40% EBITDA margin and 60% revenue growth, with no non-financial
leading performance indicators metrics. Performance in respect of
each measure will be assessed following the end of a three year
performance period ending with 2026. Details of the targets for the
EBITDA margin and revenue growth measures are included in the 2023
Directors' Remuneration Report.
The awards will "vest" on 3 October
2027 to the extent determined by reference to the assessment of the
performance condition. The awards granted to Frank Mathias and
Lucinda Crabtree will only be "released" so that they can be
exercised following the end of a further two year holding period.
The awards granted to other participants will be released at
vesting.
The Notification of Dealing Forms
set out below are provided in accordance with the requirements of
the EU Market Abuse Regulation.
Notification of Dealing Form
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Frank Mathias
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of awards over Ordinary Shares under the
Company's Long Term Incentive Plan. No consideration was paid for
the grant of awards.
|
|
c)
|
Price(s) and volumes(s)
|
2024 LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
Awards granted over 257,113 shares in
total
N/A
|
|
e)
|
Date of the transaction
|
2024-10-03
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Lucinda Crabtree
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of awards over Ordinary Shares under the
Company's Long Term Incentive Plan. No consideration was paid for
the grant of awards.
|
|
c)
|
Price(s) and volumes(s)
|
2024 LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
Awards granted over 170,113 shares in
total
N/A
|
|
e)
|
Date of the transaction
|
2024-10-03
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Sebastien Ribault
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Business Officer
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of awards over Ordinary Shares under the
Company's Long Term Incentive Plan. No consideration was paid for
the grant of awards.
|
|
c)
|
Price(s) and volumes(s)
|
2024 LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
Awards granted over 58,406 shares in
total
N/A
|
|
e)
|
Date of the transaction
|
2024-10-03
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Thierry Cournez
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Operating Officer
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of awards over Ordinary Shares under the
Company's Long Term Incentive Plan. No consideration was paid for
the grant of awards.
|
|
c)
|
Price(s) and volumes(s)
|
2024 LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
Awards granted over 51,570 shares in
total
N/A
|
|
e)
|
Date of the transaction
|
2024-10-03
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Lisa James
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief People Officer
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of awards over Ordinary Shares under the
Company's Long Term Incentive Plan. No consideration was paid for
the grant of awards.
|
|
c)
|
Price(s) and volumes(s)
|
2024 LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
Awards granted over 40,464 shares in
total
N/A
|
|
e)
|
Date of the transaction
|
2024-10-03
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Kyriacos Mitrophanous
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Innovation Officer
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of awards over Ordinary Shares under the
Company's Long Term Incentive Plan. No consideration was paid for
the grant of awards.
|
|
c)
|
Price(s) and volumes(s)
|
2024 LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
Awards granted over 52,651 shares in
total
N/A
|
|
e)
|
Date of the transaction
|
2024-10-03
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Natalie Walter
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
General Counsel
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of awards over Ordinary Shares under the
Company's Long Term Incentive Plan. No consideration was paid for
the grant of awards.
|
|
c)
|
Price(s) and volumes(s)
|
2024 LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
Awards granted over 49,169 shares in
total
N/A
|
|
e)
|
Date of the transaction
|
2024-10-03
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
-Ends-
Enquiries:
|
Oxford Biomedica plc:
Natalie Walter, Company
Secretary
|
Tel: +44 (0)1865 783 000
|
About
OXB
OXB (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell
and gene therapy, OXB has more than 25 years of experience in viral
vectors; the driving force behind the majority of cell and gene
therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus and other viral vector
types. OXB's world-class capabilities span from early stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the Tetravecta™ system), dual
plasmid system for AAV production, suspension and perfusion process
using process enhancers and stable producer and packaging cell
lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and manufacturing
facilities across Oxfordshire, UK, Lyon and Strasbourg, France and
near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn
and YouTube.